Skip Navigation

Developed via Codiak’s proprietary engEx Platform, exoSTING is engineered to provide targeted delivery to APCs in the tumor microenvironment to locally activate the innate immune response. The STING pathway is a component of the innate immune system that detects cytoplasmic DNA and helps invoke an inflammatory response. Engagement of the STING pathway has been validated to elicit an anti-tumoral response, yet therapeutic development has been generally limited by non-selective cell delivery, off-target toxicity to important immune cells in the tumor, and dose-related toxicity due to leakage of the STING agonist into the circulation. Data from Codiak’s preclinical studies suggest that, when administered intratumorally, exoSTING generates potent, targeted, and systemic anti-tumor immunity without inflammatory cytokine driven adverse events.

We are developing exoSTING for the treatment of multiple solid tumors enriched in the target APCs, initially focused on metastatic head and neck squamous cell cancer, triple-negative breast cancer, cutaneous squamous cell carcinoma, and anaplastic thyroid cancer.

We have initiated a Phase 1/2 clinical trial for exoSTING in solid tumors.

See the science

Selective Activation of APCs by exoSTING

Chart exo STING 1 mobile
Chart exo STING 2 mobile
Chart exo STING 3 mobile
Chart exo STING 4 mobile
exoSTING preferentially activates monocytes and M2 macrophages versus a STING agonist delivered without exosomes (e.g., “free”), while preserving T cell viability.
Chart exo STING 1 desktop
Chart exo STING 2 desktop
exoSTING preferentially activates monocytes and M2 macrophages versus a STING agonist delivered without exosomes (e.g., “free”), while preserving T cell viability.

exoSTING Prevents Non-Specific Intratumoral Immune Ablation

Chart exo STING 5 mobile
Free STING agonist (FSA) compared to exoSTING in anticipated results from serial tumor biopsies, showing T cell expansion and preservation and reduced off-target toxicity associated with exoSTING.
Chart exo STING 3 desktop
Free STING agonist (FSA) compared to exoSTING in anticipated results from serial tumor biopsies, showing T cell expansion and preservation and reduced off-target toxicity associated with exoSTING.